Myeloproliferative neoplasms (MPN) trials

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests adding the drug ruxolitinib to standard graft-versus-host disease (GVHD) prevention around an allogeneic stem cell transplant for older adults with myelofibrosis or MDS/MPN overlap syndromes. It has two parts: before, during, and after transplant, with ruxolitinib started before conditioning and continued for up to about a year (with taper) along with standard GVHD meds. It is for adults who are candidates for allogeneic HCT and have MF or MDS/MPN overlap, with most participants up to age 75 (some over 75 if health criteria are met). Key exclusions include contraindication to ruxolitinib, active uncontrolled infections, HIV, untreated TB, pregnancy, or a history of prior allogeneic transplant, and recent MI, stroke, or unprovoked clotting within 6 months.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study tests DISC-0974 in adults with myelofibrosis or myelodysplastic syndrome who also have anemia. - It is a phase 1b/2a open-label trial aimed at safety, tolerability, pharmacokinetics, pharmacodynamics, and to categorize anemia response. - There are MF participants (with various risk levels) and an exploratory cohort of participants with MDS and anemia. - Key exclusions include active infections (HBV/HCV or HIV with detectable viral load), recent hematopoietic stem cell transplant or related immunosuppression, recent iron chelation therapy, pregnancy, and significant heart disease. - The study is currently recruiting.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests whether markers of neutrophil extracellular traps (NETosis) can predict future thrombosis in people with certain myeloproliferative neoplasms (MPNs). It focuses on adults with JAK2V617F-positive PV, essential thrombocythemia, or pre-myelofibrosis who are at high risk for blood clots. Researchers will measure NETosis markers (calprotectin and H3Cit) at baseline and after 12 months, then follow participants for 24 months to see if these markers relate to thrombotic events and help guide prevention. Eligibility includes having the relevant MPN and high thrombotic risk, being enrolled in the AVAJAK trial and a biobank, and not having severe kidney or liver failure, being under guardianship, or using heparin at entry.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This study tests whether giving preemptive CIML natural killer (NK) cells expanded with IL-2 after a stem cell transplant can prevent relapse in adults with AML, MDS, or MDS/MPN overlap who are at high risk after transplant. It is for adults undergoing a reduced-intensity conditioning allogeneic stem cell transplant from a related donor, and plans to enroll up to about 30 participants. The trial aims to learn about the safety and potential effectiveness of CIML NK cell therapy plus IL-2 over a follow-up period of up to 3 years, with various monitoring tests along the way. Key exclusions include active infection or uncontrolled illness, pregnancy or inability to use contraception, HIV, active hepatitis B or C, prior allogeneic transplant within 7 days of infusion, and certain donor antibody or steroid-use restrictions.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study tests the drug JNJ-88549968 for people with CALR-mutated essential thrombocythemia (ET) or myelofibrosis (MF). - It aims to find a safe dose and the best dosing schedule (the RP2D) in a dose-escalation part, and then evaluate safety at that dose in an expansion part. - In US sites, the study also looks at using the drug as a stand-alone treatment and in combination with ruxolitinib or momelotinib for MF. - Eligible participants are adults (18+) with CALR mutations and ECOG 0–2; key exclusions include allergies to study drug ingredients, certain recent or active cancers (with exceptions), prior organ transplant, specific stem cell transplant history, and recent major cardiovascular disease.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This study tests INCA035784 to see if it is safe and tolerable in adults with myeloproliferative neoplasms (MPNs). - It includes participants with CALR exon-9 mutations and a confirmed MPN, such as high-risk myelofibrosis after prior treatment or high-risk essential thrombocythemia. - The trial has dose-escalation and dose-expansion parts and requires good performance status (ECOG 0-1 for the dose-escalation phase and 0-2 for the expansion phase) with certain blood test criteria. - Key exclusions include recent major bleeding or thrombosis, active or high-risk HBV/HCV/HIV infections, recent invasive cancer (with some exceptions), and pregnancy. - The study is currently recruiting and is sponsored by Incyte Corporation.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This is a multicenter screening study to find out how often the KIT D816V mutation occurs in people with suspected clonal mast cell disease. It has three cohorts: Cohort 1 includes people with suspected systemic mast cell activation disease; Cohort 2 includes people with hypermobility-related conditions, POTS, or early osteoporosis/osteopenia; Cohort 3 includes people with certain myeloid disorders per WHO criteria. The study aims to learn the prevalence of the KIT D816V mutation in these groups to inform diagnosis and future research. Exclusions include prior diagnosis of KIT-mutated monoclonal mast cell activation syndrome, cutaneous mastocytosis only, any systemic mastocytosis subtype, or mast cell sarcoma; Cohort 2 also excludes osteoporosis/osteopenia due to other known causes.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The SPEARHEAD-3 Pediatric Study is testing a treatment called afamitresgene autoleucel in children and teens with certain advanced cancers. It includes patients whose tumors express MAGE-A4 and who are HLA-A*02 positive, across cancers such as synovial sarcoma, MPNST, neuroblastoma, and osteosarcoma (ages 2-17 for synovial sarcoma; 2-21 for the other cancers). The study aims to assess safety and whether the treatment helps, after prior chemotherapy and with measurable disease before treatment. Key exclusions include HLA-A*02:05 positivity or similar A*02 variants, autoimmune disease, CNS metastases, active infections (HIV, HBV, HCV), pregnancy, significant cardiovascular disease, or another cancer not in remission.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry is being studied. Conditions: Cancer, Metastatic, Cancer, Cancer of Pancreas +40 • Eligibility: Inclusion Criteria: * Pts with solid and hematological malignancies; * Pts cancer-related biomarkers, gene variants, fusion and rearrangements (by immunohistochemistry, PCR, FISH or NGS): PD-L1, MSI (MMR), Claudin18.2,…. Goal: International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinical impact on pts with advanced cancer to facilitate clinical trial enrollment (CTE), as well as the financial impact, and potential outcomes of the intervention. Phase/Status/Sponsor: Unknown phase; RECRUITING; Massive Bio, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study tests whether adults with myeloproliferative neoplasms can complete a 12-week Cardiac Lifestyle Program that includes tailored nutrition and physical activity. - It is a single-arm, feasibility pilot enrolling about 30 participants to learn if this lifestyle intervention is doable and safe for people with MPN. - Eligibility includes adults with MPN (ET, PV, prefibrotic MF, MF, or NOS) who have at least one cardiovascular risk factor; among MF patients, only those with low or intermediate-1 risk are eligible. - Exclusions include MF with intermediate-2 or high-risk disease, ECOG performance status >2, or any condition that would prevent safe exercise.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This phase II trial tests decitabine given together with one of three drugs—ruxolitinib, fedratinib, or pacritinib—before a donor stem cell transplant for people with accelerated or blast phase myeloproliferative neoplasms. The study aims to learn how well this pre-transplant therapy works to control disease and support transplant success. Eligible participants are adults with a history of MPN and at least 5% blasts in bone marrow or blood; key exclusions include pregnancy, active infection, and certain drug interactions or prior treatments that can’t be managed. Treatment cycles include intravenous decitabine plus one of the inhibitors, with blood and bone marrow samples collected, and follow-up for up to 5 years.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This platform trial tests post-transplant cyclophosphamide-based strategies to prevent graft-versus-host disease after a mismatched unrelated donor peripheral blood stem cell transplant in adults with hematologic cancers. - It compares a new drug combination to a standard one and aims to learn which works best and is safest for GVHD prevention. - Eligible participants are adults (18 and older) receiving MMUD PBSC transplant after myeloablative or reduced-intensity conditioning, with a partially matched donor (4/8–7/8) and adequate organ function and performance status. - Key exclusions include not having a suitable donor (no 8/8 match), prior allogeneic transplant, active infection, pregnancy, or enrollment in another GVHD prevention trial.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tests pacritinib, a multi-kinase inhibitor that targets CSF1R, IRAK1, JAK2, and FLT3, in adults and youths aged 12 years and older with myelodysplastic syndromes (MDS) or MDS/MPN. - It has two parts: Phase I in 12–17 year-olds to find a safe dose, and Phase II in adults 18+ to see if pacritinib helps, measured by overall response rate in two risk-based groups. - Eligible participants must have confirmed MDS or MDS/MPN and disease status defined by prior therapy resistance or ineligibility, depending on risk. - Key exclusions include active severe bleeding, uncontrolled infection, certain heart conditions or QT prolongation risk, pregnancy, and certain drug interactions.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tests whether adding luspatercept to best supportive care can reduce the need for regular red blood cell transfusions in adults with anemia due to lower-risk MDS or non-proliferative MDS/MPN neoplasms. - It also aims to learn about the safety and tolerability of luspatercept in these patients. - Eligible participants are adults (18 or older) with MDS or non-proliferative MDS/MPN, certain splicing gene mutations, low marrow blasts, and who are refractory, intolerant to, or ineligible for prior ESA therapy and transfusion-dependent (average ≥2 units of RBCs every 8 weeks for at least 16 weeks). - The study excludes people who have had a stem cell transplant, certain del(5q) MDS without lenalidomide, uncontrolled hypertension, very low blood counts, active other cancers, or severe kidney or liver problems, as well as those who have had prior luspatercept or sotatercept, or who are pregnant. - Overall, researchers want to know if luspatercept can lessen transfusion needs while monitoring its safety in this specific MDS/MPN population.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tests Monalizumab, an anti-NKG2A antibody, in adults with AML or MDS who are undergoing haploidentical stem cell transplantation with post-transplant cyclophosphamide. - It is a Phase II, non-randomized, open-label, single-center study enrolling about 18 participants. - Participants receive 1 mg/kg Monalizumab IV on day +30 and day +44 after transplant to see if it improves graft-versus-host disease–free and progression-free survival at 1 year, and to assess safety and NK cell function. - Key exclusions include being under 18, active uncontrolled infections, CNS AML involvement, pregnancy, rapid relapse before day 30, acute GVHD before day +30, or having had a second allogeneic transplant.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests reparixin to treat myelofibrosis in adults with high-risk disease (DIPSS intermediate-2 or higher), including primary MF and MF after ET/PV, who have not tolerated or do not respond to JAK inhibitors. It is an open-label, Phase II study enrolling about 26 participants, who will take oral reparixin three times daily in 4-week cycles for a core 24-week period (with possible extension if disease is stable). The study aims to learn whether reparixin is effective, safe, and tolerable in this group and whether patients can maintain stable disease to continue therapy. Key exclusions include recent major cardiovascular events, active infections, HIV or hepatitis, recent hematopoietic cell transplant or GVHD, pregnancy, and certain drug or allergy exclusions (e.g., sulfonamides, NSAIDs).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Myeloproliferative Neoplasms (MPNs) Patient Registry is being studied. Conditions: Primary Myelofibrosis, Polycythemia Vera, Essential Thrombocythemia +7 • Eligibility: Inclusion Criteria: Diagnosis of one of the following myeloproliferative neoplasms (MPNs): * Atypical CML (aCML) * Chronic eosinophilic leukemia-not otherwise specified (CEL, NOS), * Chronic myelomonocytic leukemia (CMML)…. Goal: The mandate of this MPN registry is to collect clinical information, including molecular results, from consenting patients with a variety of MPNs at different time points during the course of their disease. Phase/Status/Sponsor: Unknown phase; RECRUITING; University Health Network, Toronto.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial is testing digital PCR to monitor measurable residual disease after allogeneic hematopoietic stem cell transplantation in people with leukemia, MDS, and related blood disorders, and it is currently recruiting. It aims to see if digital PCR can better detect MRD and predict relapse compared with standard methods like conventional qPCR or multicolor flow cytometry. Eligible participants must have had at least one fusion gene or tumor-associated mutation detected at diagnosis and must have neutrophil engraftment and have had at least one MRD test by digital PCR after transplant. Exclusions include patients who relapse or die before the first digital PCR test, and those with only DTA mutations (DNMT3A, TET2, ASXL1) or only germline mutations.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This study tests the long‑term safety of luspatercept in people who have already participated in other luspatercept trials. - It is for adults 18 and older who were in a parent luspatercept study and are either continuing treatment, crossing over from placebo, or entering long‑term follow‑up, and it uses Transition, Treatment, and Follow‑up phases plus a 42‑day safety check after the last dose. - Researchers will monitor safety and track overall survival every 6 months for at least 5 years from the first dose (or 3 years after the last dose, whichever comes later), and watch for progression to AML or other cancers. - Eligible participants must have been in the parent trial, sign informed consent, and meet visit requirements; females on treatment need pregnancy tests and contraception, while males must use a condom with pregnant partners or partners of childbearing potential. - Exclusions include pregnancy or breastfeeding, use of prohibited medications, significant medical or psychological conditions, or other factors that could interfere with safety or study data.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tests CK0804 as an add-on therapy to ruxolitinib for adults with myelofibrosis who have not had a good response to ruxolitinib. - It aims to evaluate safety and tolerability, using a safety run-in (3+3+3) and then an expansion to about 24 evaluable patients. - Eligible participants are adults with primary myelofibrosis or myelofibrosis from polycythemia vera or essential thrombocythemia who have been on ruxolitinib for at least 3 months and still have disease burden or symptoms. - Key exclusions include recent major surgery, prior stem cell transplantation, recent systemic cancer therapies (other than ruxolitinib), pregnancy, and significant organ dysfunction or other factors that could interfere with participation.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This is a small, single-arm, open-label pilot trial testing an alternating low-dose schedule of 5-azacitidine and decitabine (5AZA-alt-DEC) for people with myelodysplastic syndromes (MDS) or MDS/MPN overlap disorders. It is for adults who may respond to hypomethylating agent therapy and have evidence of prior response to HMAs, and who meet safety and performance criteria. The study aims to learn how often patients have an overall response (complete, partial, or hematologic improvement), how long responses last, and the safety profile, with correlative lab studies to explore biology. Exclusions include very high-risk MDS by IPSS-R or prior azacitidine/decitabine therapy, pregnancy, uncontrolled illness, active HIV, and other factors that could affect safety or results.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests onvansertib, a PLK1 inhibitor, in adults with recurrent or treatment-refractory chronic myelomonocytic leukemia (CMML) or MDS/MPN overlap neoplasms. It uses a dose-escalation design to find the right dose and then expands at that dose, with the drug given by mouth daily and ongoing bone marrow tests and ultrasound imaging. The study will assess safety and adverse events and look for signs of activity such as complete remission, overall remission, spleen response, and symptom changes. Eligible participants are adults with CMML or MDS/MPN overlap disease; key exclusions include progression to acute leukemia, active CNS disease, QT prolongation risk, pregnancy, and prior exposure to a PLK1 inhibitor.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The German MPN-Registry for BCR-ABL1-negative myeloid neoplasms is a registry study that collects data and stores patient samples (such as bone marrow and blood) to support research, not a treatment trial. It will analyze cell features and genetic information and study clinical characteristics, outcomes, and quality of life to identify prognostic and predictive markers. Eligible participants are adults (18 years and older) with BCR-ABL1-negative myeloid neoplasms, of any gender, at participating centers in Germany; the study is currently recruiting. Participation requires informed consent; key exclusions are severe neurological or psychiatric disorders that prevent consent, or no consent to registration, storage, and handling of personal data.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tests INCB160058 for safety, tolerability, and pharmacokinetics in people with myeloproliferative neoplasms. - It is for adults (18+) with myelofibrosis, polycythemia vera, or essential thrombocythemia who have been previously treated and may be resistant or intolerant to JAK inhibitors or standard cytoreductive therapy, with a documented JAK2V617F mutation. - The study aims to learn whether INCB160058 has an acceptable safety profile and how the drug is processed in the body in this patient group. - Key exclusions include active infections (HBV, HCV, HIV), other active cancers, recent major bleeding or thrombosis, prior stem cell transplant, abnormal lab tests, and recent or ongoing MPN-directed therapies or growth factor treatments.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study is testing whether inherited germline genetic factors predispose people to myeloproliferative neoplasms (MPN). - It is for people with an MPN diagnosis (PV, ET, pre-PMF, overt PMF, or MPN-U) who have a documented MPN driver mutation. - Eligible participants must have been diagnosed before age 27 or have at least one other case of hematologic cancer in a first- or second-degree relative. - There are no exclusion criteria for participation. - The trial is currently recruiting and is sponsored by Fondazione IRCCS Policlinico San Matteo di Pavia.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Allo HSCT Using RIC and PTCy for Hematological Diseases is being studied. Conditions: Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Biphenotypic Acute Leukemia +15 • Eligibility: Inclusion Criteria: * Age 0 to 75 years of age with Karnofsky score ≥ 70% (≥ 16 years) or Lansky score ≥ 50 (\< 16 years). * 5/6…. Goal: This is a Phase II study following subjects proceeding with our Institutional non-myeloablative cyclophosphamide/ fludarabine/total body irradiation (TBI) preparative regimen followed by a related, unrelated, or partially matched family donor stem cell infusion using post-transplant cyclophosphamide (PTCy), sirolimus and MMF GVHD prophylaxis. Phase/Status/Sponsor: Unknown phase; RECRUITING; Masonic Cancer Center, University of Minnesota.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The trial tests whether adding hyperbaric oxygen therapy around an allogeneic peripheral blood stem cell transplant is safe and whether it can improve engraftment and reduce complications like graft-versus-host disease, mucositis, infections, and neutrophil recovery. - It is for adults undergoing allogeneic PBSC transplant for certain myeloid cancers and disorders; there are two cohorts, but only the second cohort is currently recruiting. - The second cohort includes people with CMML, aCML, chronic monocytic leukemia, chronic neutrophilic leukemia, myelofibrosis, and MDS/MPN overlap syndrome. - Eligibility requires adults aged 18-75 with adequate organ function and performance status; key exclusions include pregnancy, severe lung disease needing oxygen, active infection, ear/sinus problems, claustrophobia, seizures, and ongoing tobacco use around transplant.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This phase II trial tests whether adding venetoclax to ASTX727 (decitabine plus cedazuridine) improves outcomes for bone marrow cancer in CMML and MDS/MPN with excess blasts compared with ASTX727 alone. - It is for adults with MDS/MPN overlap syndrome with at least 5% marrow blasts who meet certain health criteria. - Participants are randomly assigned to either ASTX727 plus venetoclax or ASTX727 alone, and the study looks at complete remission rates and other response and survival measures. - Key exclusions include pregnancy, uncontrolled central nervous system disease, significant cardiac disease, recent extensive prior MDS/MPN therapy, and other safety-related conditions (e.g., grapefruit product restrictions).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The trial tests whether the anticoagulants apixaban or rivaroxaban (DOACs) can prevent first-time thrombotic events better than low-dose aspirin in people with JAK2V617F-positive myeloproliferative neoplasms. It includes adults with polycythemia vera, essential thrombocythemia, or prefibrotic/primary myelofibrosis who are considered high-risk (over 60 years old or with a thrombosis history) and diagnosed within the last year. The goal is to learn if DOACs reduce thrombotic events without causing more dangerous bleeding in this disease setting. Key exclusions include contraindications to aspirin or DOACs, current use of aspirin or DOAC for another indication, inability to consent, significant liver or kidney disease, high bleeding risk, planned pregnancy, and drug interactions such as CYP3A4 inhibitors/inducers (e.g., ruxolitinib).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study aims to understand why myeloproliferative neoplasms evolve into acute myeloid leukemia by doing detailed multi-omics analyses on about 120 post-MPN AML samples. - It will identify the dysregulated pathways and test a custom ex vivo drug panel to see effects on cell survival, differentiation, and stemness. - The three best drug candidates will be validated in patient-derived xenograft models and studied for their impact on clonal evolution using single-cell sequencing. - It is for people with a prior MPN (polycythemia vera, essential thrombocythemia, or primary myelofibrosis) who have AML with ≥20% blasts and usable bone marrow material with informed consent; key exclusion is not being affiliated with the French health insurance, and the study is not yet recruiting.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tests whether itacitinib, an immune-suppressing anti-inflammatory drug, given around a non‑myeloablative haploidentical peripheral blood stem cell transplant with high-dose posttransplant cyclophosphamide, can help older patients. - Researchers want to know if itacitinib can prevent severe cytokine release syndrome after transplant, reduce graft-versus-host disease, and possibly shorten the time patients need other immune-suppressing drugs. - Participants are people aged 60 and older with certain blood cancers who have a related, partially matched donor. - Key exclusions include active CNS leukemia, HIV, active HBV or HCV requiring treatment, pregnancy, and prior/allogeneic transplant or uncontrolled infection.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This study tests Ropeginterferon alfa-2b (P1101) against anagrelide for essential thrombocythemia patients who did not respond well to hydroxyurea. It is for adults with high-risk ET who are resistant or intolerant to hydroxyurea and need a second-line therapy. Participants are randomly assigned to receive P1101 or anagrelide for 12 months, with about 14 months total for each person including screening and follow-up. The trial will evaluate efficacy and safety, including lab tests, mutation status, spleen size, and quality of life, along with routine safety assessments. Key exclusions include significant heart or lung disease, pregnancy or breastfeeding, autoimmune disease, active infections or a recent cancer, history of depression or suicidality, and factors that raise QT prolongation risk.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This is a phase 1, open-label study testing an oral drug called LY3410738, which targets IDH1 and IDH2 mutations in adults with advanced blood cancers. - The study has two parts: dose escalation to find the maximum tolerated dose, followed by dose expansion to further assess safety and signs of activity in five cohorts. - Eligible participants include people with IDH-mutant advanced hematologic malignancies who have received prior therapy; in some arms, older AML patients or relapsed/refractory AML patients (US only) may enroll. - Key exclusions include active infection or active CNS disease, recent stem cell transplant or CAR-T therapy, pregnancy, and certain drug interactions or other serious conditions.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This is a prospective, multi-center trial testing a combination of decitabine (DEC) and venetoclax (VEN) for AML that developed from myeloproliferative neoplasms in patients who are unfit for intensive chemotherapy. - The goal is to learn whether VEN plus DEC can improve survival outcomes in these patients. - Eligible participants are adults with newly diagnosed, untreated sAML due to MPNs who are considered unfit for intensive treatment, have ECOG 0-2 (or reversible ECOG 3 with supportive care), can consent, and, for men with partners, will use barrier contraception. - Key exclusions include de novo AML, serious organ dysfunction (heart, liver, kidney), HIV, uncontrolled infections, QTc prolongation, and a history of cancer not in remission with limited life expectancy. - The trial is currently active but not recruiting, sponsored by Gruppo Italiano Malattie EMatologiche dell'Adulto.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study tests a GIMEMA platform to collect patient-reported outcomes about quality of life and symptom burden in Italian patients with Philadelphia chromosome negative myeloproliferative neoplasms. - It aims to learn how the disease and its treatments affect wellbeing, symptoms, and daily functioning. - It includes adults in Italy with PV, ET, or PMF (including pre-PMF, overt-PMF, and MF after ET or PV) diagnosed within the past year, who have completed a baseline PRO assessment. - Participants must be able to read Italian and have no major psychiatric or cognitive disorders that would hinder self-reporting. - The trial is currently active but not recruiting.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Tissue Microarray of Hematological Malignancies is being studied. Conditions: Hematological Malignancies • Eligibility: Inclusion Criteria: * hematological malignancy/neoplasm Exclusion Criteria: * Non-sufficient data available. Goal: The aim of the study is to create new tools for improving management of patients with hematological malignancies by combining extensive clinical data from patients newly diagnosed with hematological malignancies and innovative laboratory analyses made on available tissue samples in regional biobanks from these patients. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Tampere University Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The Registry of Patients With MPNs in Taiwan is an observational registry that collects clinical data, molecular characteristics, treatment details, and responses in people with myeloproliferative neoplasms. It aims to understand how MPNs are diagnosed and treated in Taiwan, including high-molecular-risk gene information, and to track complications and survival. Eligible participants are adults 20 years and older with a confirmed Ph(-) MPN by the 2016 WHO criteria, and they must consent to participate; those who don’t meet criteria or don’t sign consent are excluded. The study is currently active but not recruiting.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies is being studied. Conditions: Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Mantle Cell Lymphoma (MCL) +9 • Eligibility: Inclusion Criteria: * Willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures * Histologically or cytologically confirmed diagnosis…. Goal: This is a Phase 1 dose-escalation study of PRT2527, a potent and highly selective cyclin-dependent kinase (CDK) 9 inhibitor, in participants with select relapsed or refractory (R/R) hematologic malignancies. The purpose of this study is to evaluate the safety, tolerability, recommended phase 2 dose (PR2D), and preliminary efficacy of PRT2527 as a monotherapy and in combination with zanubrutinib or venetoclax. Phase/Status/Sponsor: Unknown phase; COMPLETED; Prelude Therapeutics.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

In Vitro Drug Sensitivity Testing of Fresh Human Samples is being studied. Conditions: Myeloproliferative Disorders, Lymphoproliferative Disorders • Eligibility: Inclusion Criteria: * Index cases: patients with myeloproliferative or lymphoproliferative disorders. * Controls: patients without hematological disease, without chemotherapy ((≤ 5 years.) and without immunosuppressive treatment at the…. Goal: Hematological malignancies gather several various pathologies included myeloproliferative disorders (as acute myeloid leukemia (AML) or chronic myeloid leukemia (CML)) and lymphoproliferative disorders (as chronic lymphoid leukemia (CLL), non-Hodgkin lymphoma (NHL) and multiple myeloma (MM)) . Over the last decade, the treatments have evolved significantly but the overall survival remains limited, especially for the AML and MM patients. Phase/Status/Sponsor: Unknown phase; UNKNOWN; Hospices Civils de Lyon.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Myeloablative Hematopoietic Progenitor Cell Transplantation (HPCT) for Pediatric Malignancies is being studied. Conditions: Leukemia, Myelogenous, Chronic, Leukemia, Lymphoblastic, Acute, Leukemia, Myelogenous, Acute +2 • Eligibility: Inclusion Criteria: * Malignant Disease * Chronic myleogenous leukemia in chronic or accelerated phase * Acute lymphoblastic leukemia (ALL) * First remission high-risk ALL (Ph+, t( 4-11) infants).…. Goal: The purpose of this study is to show that myeloablative hematopoietic progenitor cell transplantation (HPCT) continues to offer acceptable disease-free survival for select patients requiring HPCT. Phase/Status/Sponsor: Unknown phase; COMPLETED; Ann & Robert H Lurie Children's Hospital of Chicago.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving is being studied. Conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome +1 • Eligibility: Inclusion Criteria: 1. Male and female patients aged ≥ 18 years. 2. Patients with relapsed /refractory AML, ALL, or MLL with rearrangement of the MLL gene, including 11q23…. Goal: The purpose of this study is to determine the safe dose of EPZ-5676, to evaluate the safety of EPZ-5676 in patients with advanced hematologic malignancies, and to conduct a preliminary assessment of the anti-leukemia activity of EPZ-5676 in patients with acute leukemias bearing rearrangements of the MLL gene. Currently this study is in the MLL-r restricted/expansion phase and is only enrolling patients with rearrangements involving the MLL gene, including 11q23 or partial tandem duplications (PTD). Phase/Status/Sponsor: Unknown phase; COMPLETED; Epizyme, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

CD8+ Memory T-Cells as Consolidative Therapy After Donor Non-myeloablative Hematopoietic Cell Transplant in Treating Patients With Leukemia or Lymphoma is being studied. Conditions: Acute Myeloid Leukemia, B-Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia +4 • Eligibility: Inclusion Criteria: * Must have a human leukocyte antigen (HLA)-matched or single allele-mismatched adult sibling serving as donor * Must have a myeloid or lymphoid malignant disease that…. Goal: This phase 2 trial studies how well cluster of differentiation 8 (CD8)+ memory T-cells work as a consolidative therapy following a donor non-myeloablative hematopoietic cell transplant in treating patients with leukemia or lymphoma. Giving total lymphoid irradiation and anti-thymocyte globulin before a donor hematopoietic cell transplant helps stop the growth of cells in the bone marrow, including normal blood-forming cells (stem cells) and cancer cells. Phase/Status/Sponsor: Unknown phase; COMPLETED; Robert Lowsky.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies is being studied. Conditions: Acute Myeloid Leukemia, Acute Leukemia, Chronic Myelogenous Leukemia +8 • Eligibility: Inclusion Criteria: * Patients with the following diseases: * Acute myeloid or lymphocytic leukemia in first remission at standard or high-risk for recurrence. * Acute leukemia in greater…. Goal: New conditioning regimens are still needed to maximize efficacy and limit treatment-related deaths of allogeneic transplantation for advanced hematologic malignancies. Over the past several years, the investigators have evaluated several new conditioning regimens that incorporate fludarabine, a novel immunosuppressant that has limited toxicity and that has synergistic activity with alkylating agents. Phase/Status/Sponsor: Unknown phase; COMPLETED; University of Illinois at Chicago.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer is being studied. Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma +4 • Eligibility: DISEASE CHARACTERISTICS: * Diagnosis of a hematologic malignancy of 1 of the following high-risk types: * Acute lymphoblastic leukemia * Acute myeloid leukemia * Chronic myelogenous leukemia *…. Goal: RATIONALE: Giving low doses of chemotherapy, such as fludarabine and busulfan, before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells. Phase/Status/Sponsor: Unknown phase; COMPLETED; OHSU Knight Cancer Institute.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Perifosine in Treating Patients With Refractory Solid Tumors or Hematologic Cancer is being studied. Conditions: Leukemia, Lymphoma, Myelodysplastic Syndromes +2 • Eligibility: DISEASE CHARACTERISTICS: * Histologically confirmed solid tumor, non-Hodgkin's lymphoma, chronic lymphocytic leukemia, myelodysplastic syndromes, or Hodgkin's lymphoma that has no effective standard therapeutic option but requires systemic therapy…. Goal: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of perifosine in treating patients who have refractory solid tumors or hematologic cancer. Phase/Status/Sponsor: Unknown phase; COMPLETED; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain is being studied. Conditions: Cancer • Eligibility: Inclusion Criteria: * Male or female, ≥ 18 years of age. * Diagnosis of cancer. * Opioid-tolerant. Subjects who were opioid tolerant were those taking ≥ 60 mg…. Goal: This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain. The study medication is administered under the tongue as a simple spray and can be self-administered by patients or assisted by their caregivers. Phase/Status/Sponsor: Unknown phase; COMPLETED; INSYS Therapeutics Inc.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment is being studied. Conditions: Brain Tumor, Central Nervous System Tumors, Cachexia +5 • Eligibility: INCLUSION CRITERIA: * Any cachectic patient with weight loss presumed secondary to cancer or cancer related therapy is eligible. Cachexia is defined as having one or more of…. Goal: RATIONALE: Cyproheptadine and megestrol may improve appetite and help prevent weight loss in children with cancer. PURPOSE: This phase II trial is studying how well cyproheptadine and megestrol work in improving appetite and preventing weight loss in children with cachexia caused by cancer or cancer treatment. Phase/Status/Sponsor: Unknown phase; COMPLETED; University of South Florida.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Unrelated Stem Cell Transplantation for Adults With Hematopoietic Disorders is being studied. Conditions: CML, ALL, AML +3 • Eligibility: Inclusion Criteria: * Age \>15 and \<55 * Adequate renal function with serum creatinine \<2.0 mg/dl * Pulmonary diffusing capacity\>50% of predicted * Cardiac ejection fraction \>40% as…. Goal: This study performs HLA matched stem cell transplantation from unrelated donors in adults who require stem cell transplantation but do not have a matched related donor available. The incidence of graft-versus-host disease in unrelated stem cell transplantation is recorded. Phase/Status/Sponsor: Unknown phase; COMPLETED; University of California, San Francisco.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Pyroxamide in Treating Patients With Advanced Cancer is being studied. Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma +5 • Eligibility: DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed solid tumor or hematologic malignancy * Disease that has failed standard therapies (e.g., surgery, radiotherapy, endocrine therapy, or chemotherapy) or for…. Goal: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of pyroxamide in treating patients who have advanced cancer. Phase/Status/Sponsor: Unknown phase; COMPLETED; Memorial Sloan Kettering Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer is being studied. Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma +4 • Eligibility: DISEASE CHARACTERISTICS: Histologically confirmed malignancy Malignant lymphoma - Non-Hodgkin's lymphoma Intermediate and high grade (aggressive) histology with primary refractory disease or relapsed following standard therapy - Hodgkin's disease…. Goal: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. Phase/Status/Sponsor: Unknown phase; COMPLETED; Cancer Treatment Centers of America.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Advanced Hematologic Cancer is being studied. Conditions: Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes +1 • Eligibility: DISEASE CHARACTERISTICS: * Diagnosis of one of the following: * Infant leukemia * Acute lymphoblastic leukemia in 3rd or greater remission or relapse * Undifferentiated or biphenotypic leukemia…. Goal: RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more cancer cells. Phase/Status/Sponsor: Unknown phase; COMPLETED; Memorial Sloan Kettering Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Tipifarnib in Treating Patients With Advanced Hematologic Cancer is being studied. Conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma +2 • Eligibility: DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed hematologic malignancy refractory to standard therapy or for which no known effective therapy exists * Hodgkin's or non-Hodgkin's lymphoma * Known…. Goal: Randomized phase I trial to study the effectiveness of tipifarnib in treating patients who have advanced hematologic cancer. Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Phase/Status/Sponsor: Unknown phase; COMPLETED; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies is being studied. Conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) +97 • Eligibility: Inclusion Criteria: * Patients must be not eligible for conventional transplants and must have disease expected to be stable for at least 100 days without chemotherapy; patients with…. Goal: This phase II trial studies the side effects and the best dose of alemtuzumab when given together with fludarabine phosphate and low-dose total body irradiation (TBI) and how well it works before donor stem cell transplant in treating patients with hematological malignancies. Giving chemotherapy and low-dose TBI before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells. Phase/Status/Sponsor: Unknown phase; COMPLETED; Fred Hutchinson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests an oral drug called LP-118 in adults whose blood cancers have relapsed or are refractory, and it plans to enroll up to 100 participants. It is a Phase 1 study with dose-escalation (Phase 1a) and expansion (Phase 1b) to assess safety, tolerability, and how the drug behaves in the body. It aims to find the maximum tolerated dose or the recommended dose for future studies and to gather early signs of activity across several relapsed/refractory blood cancers, including CLL/SLL, AML, NHL, MM, and ALL. Key exclusions include recent stem cell transplant or active GVHD, uncontrolled infections, significant heart problems or QT prolongation, pregnancy, and the inability to take oral medication. The study is sponsored by Newave Pharmaceutical Inc and is currently recruiting at multiple centers.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Alemtuzumab, Busulfan, and Cyclophosphamide Followed By a Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer is being studied. Conditions: Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes +1 • Eligibility: DISEASE CHARACTERISTICS: * Confirmed diagnosis of one of the following: * Primary acute myeloid leukemia (AML) meeting any of the following criteria: * First complete remission (CR; defined…. Goal: RATIONALE: Monoclonal antibodies, such as alemtuzumab, can find cancer cells and either kill them or deliver cancer-killing substances to them without harming normal cells. Giving chemotherapy drugs, such as busulfan and cyclophosphamide, before a donor stem cell transplant helps stop the growth of cancer cells. Phase/Status/Sponsor: Unknown phase; TERMINATED; Fred Hutchinson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Blood Samples From Patients on a Clinical Trial to CINV During HSCT is being studied. Conditions: Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor +9 • Eligibility: DISEASE CHARACTERISTICS: * Previously collected serum samples from patients with cancer enrolled on the placebo arm of the pilot aprepitant study * Patients treated with busulfan/cyclophosphamide or cyclophosphamide/total…. Goal: RATIONALE: Studying samples of blood in the laboratory from patients with cancer may help doctors learn more about nausea and vomiting caused by cancer treatment. PURPOSE: This laboratory study is looking at blood samples from patients with cancer who were treated on a clinical trial to control nausea and vomiting during donor stem cell transplant. Phase/Status/Sponsor: Unknown phase; TERMINATED; OHSU Knight Cancer Institute.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Umbilical Cord Blood Transplant for Hematologic Cancer is being studied. Conditions: Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia +4 • Eligibility: DISEASE CHARACTERISTICS: * Diagnosis of 1 of the following hematologic malignancies: * Acute myeloid leukemia (AML) with or without history of myelodysplastic syndromes, meeting 1 of the following…. Goal: RATIONALE: Giving low doses of chemotherapy, such as fludarabine and cyclophosphamide, and radiation therapy before a donor umbilical cord blood stem cell transplant helps stop the growth of cancer cells. It also stops the patient's immune system from rejecting the donor's stem cells. Phase/Status/Sponsor: Unknown phase; TERMINATED; University of Rochester.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Presence of Donor-Derived DNA in Semen Samples From Cancer Survivors Who Underwent Donor Stem Cell Transplant is being studied. Conditions: Cancer Survivor, Chronic Myeloproliferative Disorders, Leukemia +6 • Eligibility: DISEASE CHARACTERISTICS: * Disease in remission * More than 365 days since prior allogeneic hematopoietic stem cell transplantation with history of full donor engraftment * Stable complete donor…. Goal: RATIONALE: Studying samples of semen from cancer survivors in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This phase I research study is looking at the presence of donor-derived DNA in semen samples form cancer survivors who underwent donor stem cell transplant. Phase/Status/Sponsor: Unknown phase; TERMINATED; Vanderbilt University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Total-Body Irradiation, Fludarabine, and Alemtuzumab Followed By Stem Cell Transplant in Treating Patients With Myeloproliferative Disorder, MS, AML, or CML is being studied. Conditions: Chronic Myeloproliferative Disorders, Leukemia, Myelodysplastic Syndromes • Eligibility: INCLUSION CRITERIA: * Myelodysplastic syndrome with IPSS score \> 0.(Appendix B) Or * Myeloproliferative disorders * Primary Myelofibrosis with Lile score of 1 or 2 (Appendix C) *…. Goal: Patients are being asked to participate in this study because they have a malignant blood disease such as Myelodysplastic Syndrome (MDS), Myeloproliferative Disorder (MPD), Acute Myelogenous Leukemia (AML) or Chronic Myelogenous Leukemia (CML). We feel that patients could benefit from an allogeneic (meaning the cells come from a donor other than themself) stem cell transplant. Phase/Status/Sponsor: Unknown phase; TERMINATED; Baylor College of Medicine.

This summary may be inaccurate. Verify against ClinicalTrials.gov.